Dr Damian Deavall
Damian is a project leader with broad expertise in global drug development across multiple modalities, including small molecules, antibodies, peptides, oligonucleotides, therapeutic viruses and vaccines. He has 20 years of experience in the pharmaceutical industry from early phase discovery, through development to registration across multiple therapy areas including oncology, infectious disease and metabolic disorders. He has led the safety assessment of more than 30 candidate drug programmes, bringing new therapies to clinical trials at all phases and completing marketing approval applications in the EU and US. He specializes in leading and managing drug safety programmes within complex alliances and partnerships. Damian brings wit and wisdom to projects to drive a cross-discipline collaboration.